Welcome to our dedicated page for Lakewood-Amedex Biotherapeutics SEC filings (Ticker: LABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lakewood-Amedex Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lakewood-Amedex Biotherapeutics's regulatory disclosures and financial reporting.
Lakewood-Amedex Biotherapeutics Inc. registers 9,647,726 shares of Common Stock for resale, composed of 9,375,000 shares issuable upon conversion of Series C Preferred Stock and 272,726 shares held by RBW Capital Partners LLC.
The prospectus states the company will receive no proceeds from these resales and that sales may occur at fixed, market, negotiated or other prices through underwriters, brokers, agents, or directly by the selling stockholders. The company paid registration expenses; selling stockholders bear selling commissions and transfer taxes.
Lakewood-Amedex Biotherapeutics Inc. director Tucker Joseph Edward received a grant of warrants to acquire 33,784 shares of Common Stock. The warrants carry an exercise price of $10.00 per share and were awarded as a grant/award acquisition, not an open-market purchase.
The warrants vest in four equal tranches of 8,446 warrants on October 24, 2026, April 24, 2027, October 24, 2027, and April 24, 2028, and expire on April 23, 2036. Following this grant, 33,784 derivative securities of this type are reported as directly held.
Lakewood-Amedex Biotherapeutics Inc. director Tucker Joseph Edward filed an initial Form 3 reporting his beneficial ownership in the company. The filing lists his direct holdings of common stock at 0 shares following the reporting date, and shows no reported purchases, sales, or option exercises.
Lakewood-Amedex Biotherapeutics Inc. director Leonard James DeRoma filed an initial Form 3 showing his existing stake in the company. He reports direct ownership of 187,736 shares of common stock.
DeRoma also holds several series of warrants to acquire common stock at exercise prices ranging from $2.13 to $5.92 per share, with expiration dates between 2028 and 2032. The filing reflects current holdings rather than new purchases or sales.
Lakewood-Amedex Biotherapeutics Inc. Chief Medical Officer Thomas Balzer filed an initial ownership report describing his equity stake in the company. He directly holds 255,322 shares of common stock.
He also holds several stock options: rights to buy 168,919 shares of common stock at an exercise price of $2.31 per share expiring on July 1, 2035, and options to buy 46,115, 33,784, and 50,676 shares at an exercise price of $2.13 per share, expiring on March 13, 2034, March 1, 2033, and November 13, 2032, respectively. The filing records these positions as holdings rather than new purchases or sales.
Lakewood-Amedex Biotherapeutics Inc. director and CEO Kelvin Cooper has filed an initial Form 3 detailing his holdings in LABT. He directly holds 300,594 shares of common stock. He also holds several stock options to buy common shares at exercise prices between $2.13 and $2.78 per share, with expiration dates ranging from 2031 to 2035.
Lakewood-Amedex Biotherapeutics Inc. Chief Financial Officer Peter Ceccacci filed an initial ownership report showing his equity position in the company. He directly holds 468,148 shares of common stock.
He also holds several direct stock options on common shares, including 202,703 underlying shares at an exercise price of $2.31 per share expiring in 2035, and additional options at exercise prices of $2.13 and $2.78 per share with expirations between 2031 and 2034. The filing records holdings only and does not show new purchases or sales.
Lakewood-Amedex Biotherapeutics Inc. has filed a Form S-1 covering the resale of up to 9,647,726 shares of common stock. This includes 9,375,000 shares issuable upon conversion of Series C Preferred Stock sold in a January 2026 private placement and 272,726 shares issued to RBW Capital Partners LLC as advisory compensation. The company will not receive proceeds from these resales, though it previously raised $7.5 million via the Series C financing and short-term notes.
Lakewood-Amedex is a clinical-stage biotechnology company developing Bisphosphocin antimicrobial candidates, led by Nu-3 gel for mildly infected diabetic foot ulcers, and early-stage programs for urinary tract and pulmonary infections. For 2025, the company reported no revenue, a net loss of $3.85 million, cash of $236,400, total assets of $481,598, liabilities of $2.45 million, and a stockholders’ deficit of $1.96 million, with its auditors expressing substantial doubt about its ability to continue as a going concern. It qualifies as an emerging growth and smaller reporting company, using scaled disclosure and extended accounting transition relief.
Lakewood-Amedex Biotherapeutics appointed Dr. Joseph Tucker to its Board effective April 24, 2026. He will serve until the 2027 annual meeting. The Board agreement requires attendance at two to four meetings per year and reimbursement of pre-approved travel and living expenses.
Dr. Tucker will receive $6,000 per quarter payable in common stock and was granted 33,784 warrants exercisable at $10.00 per share for ten years. The warrants vest in four equal tranches on October 24, 2026, April 24, 2027, October 24, 2027, and April 24, 2028; unvested warrants are cancelled if the Company terminates the agreement.